Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Perfusion
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Palmér, K.
Right arrow Articles by Frenckner, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palmér, K.
Right arrow Articles by Frenckner, B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Carmeda surface heparinization in neonatal ECMO systems: long-term experiments in a sheep model

K. Palmér

Department of Pediatric Anesthesiology, St Goran's Hospital, Karolinska Institute

H. Ehrén

Department of Pediatric Surgery, St Goran's Hospital, Karolinska Institute

R. Benz

Department of Clinical Chemistry St Goran's Hospital, Karolinska Institute

B. Frenckner

Department of Pediatric Surgery, St Göran's Hospital, Karolinska Institute, Stockholm

The thromboresistance in three Carmeda (Stockholm, Sweden) heparin- coated neonatal ECMO systems with a runtime of 45, 56 and 96 hours, respectively, and three noncoated systems with a runtime of 12, 42 and 66 hours, respectively, were compared using a sheep model. The flow rate was 200 ml/min and the activated clotting time (ACT) was kept at approximately 120 seconds. At the end of the experiment, the heparin-coated systems only contained minimal clotting while the controls showed major clotting in the entire system. Fibrin monomers were not detected until after 24 hours in the heparin- coated group, but demonstrated within 60 minutes in the noncoated group.

It is concluded that the Carmeda heparin coating has a thromboresistant effect, and may be used to reduce the need for systemic heparinization in ECMO treatment of neonates.

Perfusion, Vol. 10, No. 5, 307-313 (1995)
DOI: 10.1177/026765919501000505
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 PerfusionHome page
J. B Zwischenberger and S. K Alpard
Artificial lungs: a new inspiration
Perfusion, July 1, 2002; 17(4): 253 - 268.
[Abstract] [PDF]